(MENAFN) As CEO Kare Schultz seeks to reduce USD1.5 billion to USD2 billion in costs over the next two years, Teva Pharmaceutical Industries Ltd is considering cutting up to 10,000 jobs, according to a report by Bloomberg.

U.S.-listed shares of the debt-laden Israeli drugmaker jumped as much as 7 percent to USD16.09 on Friday.

However, no final decision has been taken, and the targets may be modified, with a range of 5,000 to 10,000 jobs being discussed, Bloomberg reported.

MENAFN0912201700450000ID1096210280